NKA Bio Inc

NKA Bio is currently focused on creating NKA01 which is an antibody to treat critically injured patients to extend time for treatment and reduce their time and costs of ICU . A prototype of our drug obtained 100% survival vs the standard treatment which had 0% survival.  NKA01 will be a temperature stable injectable that can be used in the field or in the hospital. When brought to market our solution will make lives better by getting more bleeding patients to the hospital  and reducing the time spent in the ICU.